Application of a lncrna SGOL1-AS1 as a diagnostic marker for gastric cancer
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CANCER CENT OF GUANGZHOU MEDICAL UNIV
- Publication Date
- 2021-02-26
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
Technical field
[0001] The present invention relates to the technical field of gastric cancer diagnosis, and more specifically, to the application of an lncRNA SGOL1-AS1 as a gastric cancer diagnostic marker.Background technique
[0002] Gastric cancer is one of the highest incidence of malignant tumors in the world. It ranks fourth in incidence and second in mortality among all malignant tumors. There are up to 1 million new cases of gastric cancer worldwide each year, and about 700,000 patients die. The 5-year survival rate is less than 20%, and the 5-year survival rate after treatment for early gastric cancer can reach more than 90%. Therefore, early diagnosis is very important to improve the efficacy of gastric cancer. At present, the most valuable method for gastric cancer diagnosis is gastroscopy. However, gastroscopy is an invasive examination and is not suitable as a routine screening examination. At present, the clinical markers of gastric cancer mainly include CEA, CA19-9, CA-12...